- |||||||||| GT-002 / Glycotope
Targeting of a cancer-associated LYPD3 glycoform for tumor therapy (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1650;
By using this approach, we were able to develop an anti-LYPD3 antibody that stains cancer tissue of various indications while showing drastically reduced off-tumor binding towards healthy LYPD3-positive tissues. We believe that this highly specific antibody is exceptionally suitable for potent therapies like ADCs, radio-conjugates and CARs.
- |||||||||| lupartumab amadotin (BAY1129980) / Bayer
Trial termination, Metastases: Dose-escalation Study of Lupartumab Amadotin (BAY1129980) (clinicaltrials.gov) - Dec 11, 2019
P1, N=69, Terminated,
We believe that this highly specific antibody is exceptionally suitable for potent therapies like ADCs, radio-conjugates and CARs. Completed --> Terminated
- |||||||||| lupartumab amadotin (BAY1129980) / Bayer
Trial completion, Trial completion date, Metastases: Dose-escalation Study of Lupartumab Amadotin (BAY1129980) (clinicaltrials.gov) - Sep 20, 2018
P1, N=70, Completed,
Completed --> Terminated Active, not recruiting --> Completed | Trial completion date: Apr 2020 --> Aug 2018
- |||||||||| lupartumab amadotin (BAY1129980) / Bayer
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Dose-escalation Study of Lupartumab Amadotin (BAY1129980) (clinicaltrials.gov) - Jul 16, 2018
P1, N=70, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: Apr 2020 --> Aug 2018 Recruiting --> Active, not recruiting | N=117 --> 70 | Trial primary completion date: Apr 2020 --> Sep 2018
- |||||||||| lupartumab amadotin (BAY1129980) / Bayer
Trial completion date, Trial primary completion date, IO biomarker, Metastases: Dose-escalation Study of Lupartumab Amadotin (BAY1129980) (clinicaltrials.gov) - Mar 9, 2018
P1, N=117, Recruiting,
Recruiting --> Active, not recruiting | N=117 --> 70 | Trial primary completion date: Apr 2020 --> Sep 2018 Trial completion date: Dec 2018 --> Apr 2020 | Trial primary completion date: Dec 2018 --> Apr 2020
- |||||||||| lupartumab amadotin (BAY1129980) / Bayer
Enrollment change, IO biomarker, Metastases: Dose-escalation Study of Lupartumab Amadotin (BAY1129980) (clinicaltrials.gov) - Feb 6, 2018
P1, N=142, Recruiting,
Trial completion date: Dec 2018 --> Apr 2020 | Trial primary completion date: Dec 2018 --> Apr 2020 N=90 --> 142
- |||||||||| lupartumab amadotin (BAY1129980) / Bayer
Trial primary completion date, IO biomarker, Metastases: Dose-escalation Study of Lupartumab Amadotin (BAY1129980) (clinicaltrials.gov) - Feb 14, 2017
P1, N=90, Recruiting,
N=90 --> 142 Trial primary completion date: Dec 2017 --> Dec 2018
- |||||||||| lupartumab amadotin (BAY1129980) / Bayer
Trial primary completion date, IO biomarker, Metastases: Dose-escalation Study of Lupartumab Amadotin (BAY1129980) (clinicaltrials.gov) - May 13, 2016
P1, N=90, Recruiting,
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Apr 2017 --> Dec 2017
- |||||||||| lupartumab amadotin (BAY1129980) / Bayer
Trial primary completion date, IO biomarker, Metastases: Dose-escalation Study of Lupartumab Amadotin (BAY1129980) (clinicaltrials.gov) - Nov 15, 2015
P1, N=60, Recruiting,
N=60 --> 90 Trial primary completion date: Apr 2016 --> Apr 2017
- |||||||||| lupartumab amadotin (BAY1129980) / Bayer
Enrollment open, IO biomarker, Metastases: Dose-escalation Study of Lupartumab Amadotin (BAY1129980) (clinicaltrials.gov) - May 29, 2014
P1, N=60, Recruiting,
Trial primary completion date: Apr 2016 --> Apr 2017 Not yet recruiting --> Recruiting
|
